What is Epitopix?
Epitopix operates at the intersection of biotechnology and agricultural science, focusing on the development and manufacturing of innovative veterinary vaccines. The company is recognized for its proprietary Siderophore Receptors and Porins (SRP) technology, which allows for the creation of highly targeted autogenous vaccines. These solutions are specifically engineered to address bacterial and viral pathogens in poultry, bovine, and swine populations.
By prioritizing disease prevention and the enhancement of livestock performance, Epitopix provides critical infrastructure for the food animal health sector. Its market position is defined by a commitment to high-quality, custom-made vaccine solutions that mitigate the economic impact of disease outbreaks in industrial farming environments. The company's technical expertise in immunology positions it as a key player in the global effort to improve animal welfare and food security.
How much funding has Epitopix raised?
Epitopix has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Epitopix
PPP
Public-Private Partnership
What's next for Epitopix?
Looking ahead, the strategic deployment of this late-stage funding will likely focus on expanding manufacturing capacity and broadening the reach of its SRP-based vaccine portfolio. As the company transitions into its next phase of growth, the focus will shift toward scaling commercial operations and potentially exploring new therapeutic applications for its core technology. The current financial backing provides the necessary runway to navigate regulatory landscapes and deepen market penetration in key agricultural regions.
Furthermore, the company is expected to leverage its strengthened balance sheet to pursue operational efficiencies, ensuring that its vaccine production remains both scalable and cost-effective. By maintaining a rigorous focus on scientific innovation and market-driven product development, Epitopix is poised to sustain its competitive advantage in the evolving landscape of veterinary biotechnology.
